RE:Perspective I don't like the deal, but this is false. 30% does not mean 40 M$ US it includes warrants and a possible increase of 15% of the offeering. So 30% dilution is for around 72 M$ US, so 92 M$ CAN. Still bad, but not close to what you say.
jeffm34 wrote: To put this deal in perspective, the company just sold 30% of all future revenues for Egrifta, Tragarzo, any Nash drug, and any oncology drug for $40M.